1-855-RxRxCSS / 1-855-797-9277

Clinical Trials

print-iconemail-iconshare-icon

As part of our mission to deliver the latest medical breakthroughs, CSSIFM physicians conduct clinical trials that test new treatments for a wide range of patients and cancer types. The following trials are being conducted at CSSIFM and new ones are on the horizon. Please fill out the Clinical Trial Inquiry to get more information.

Clinical Trial Inquiry


Any information submitted using this form is transmitted securely.

PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
https://clinicaltrials.gov/ct2/show/NCT04050709
Indication: Advanced or Metastatic Solid Tumors
NCT04050709| QUILT-3.064


Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
https://clinicaltrials.gov/ct2/show/NCT03773302
Indication: Advanced Cholangiocarcinoma
NCT03773302| QBGJ398-301


A Phase 2, Open-Label, Randomized Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC
https://clinicaltrials.gov/ct2/show/NCT03520686
Indications: Non Small Cell Lung Cancer
NCT03520686 | QUILT 2.023


A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
https://clinicaltrials.gov/ct2/show/NCT03228667
Indications: Non-Small Cell Lung Cancer
NCT03228667 | QUILT 3.055


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Clear Cell Sarcoma that Contains the EWSR1-ATF1 Gene Fusion
https://clinicaltrials.gov/ct2/show/NCT03132155
Indication: Clear Cell Sarcoma
NCT03132155 | QUILT-3.031


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Solid Tumors that Overexpress MET or Harbor MET EXON 14Skipping (METEX14DEL) Mutations
https://clinicaltrials.gov/ct2/show/NCT03147976
Indication: Solid Tumors
NCT03147976 | Quilt-3.036


An Open-label, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03127124
Indications: Pancreatic Adenocarcinoma
NCT03127124 | QUILT 2.022


NANT Neoepitope Yeast Vaccine (Ye-Neo-001): Adjuvant Immunotherapy Using A Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects With Previously Treated Cancers
https://clinicaltrials.gov/ct2/show/NCT03552718
Indications: Solid Cancers
NCT03552718 | QUILT 2.025

For More Information

1-855-RxRxCSS

1-855-797-9277


CSSIFM
El Segundo
2040 East Mariposa Avenue
El Segundo, California 90245
Phone: 213 266 5600
Fax: 562 548 2304

Costa Mesa
1640 Newport Blvd. Suite 370
Costa Mesa, CA 92627
Phone: 949 288 5701
Fax: 949 629 3806

We are not currently accepting walk-ins. Please call to schedule an appointment.

Costa Mesa

El Segundo

As part of our mission to deliver the latest medical breakthroughs, CSSIFM physicians conduct clinical trials that test new treatments for a wide range of patients and cancer types. The following trials are being conducted at CSSIFM and new ones are on the horizon. Please fill out the Clinical Trial Inquiry to get more information.

Clinical Trial Inquiry



Any information submitted using this form is transmitted securely.

PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
https://clinicaltrials.gov/ct2/show/NCT04050709
Indication: Advanced or Metastatic Solid Tumors
NCT04050709| QUILT-3.064


Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
https://clinicaltrials.gov/ct2/show/NCT03773302
Indication: Advanced Cholangiocarcinoma
NCT03773302| QBGJ398-301


A Phase 2, Open-Label, Randomized Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC
https://clinicaltrials.gov/ct2/show/NCT03520686
Indications: Non Small Cell Lung Cancer
NCT03520686 | QUILT 2.023


A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
https://clinicaltrials.gov/ct2/show/NCT03228667
Indications: Non-Small Cell Lung Cancer
NCT03228667 | QUILT 3.055


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Clear Cell Sarcoma that Contains the EWSR1-ATF1 Gene Fusion
https://clinicaltrials.gov/ct2/show/NCT03132155
Indication: Clear Cell Sarcoma
NCT03132155 | QUILT-3.031


A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Solid Tumors that Overexpress MET or Harbor MET EXON 14Skipping (METEX14DEL) Mutations
https://clinicaltrials.gov/ct2/show/NCT03147976
Indication: Solid Tumors
NCT03147976 | Quilt-3.036


An Open-label, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03127124
Indications: Pancreatic Adenocarcinoma
NCT03127124 | QUILT 2.022


NANT Neoepitope Yeast Vaccine (Ye-Neo-001): Adjuvant Immunotherapy Using A Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects With Previously Treated Cancers
https://clinicaltrials.gov/ct2/show/NCT03552718
Indications: Solid Cancers
NCT03552718 | QUILT 2.025

Clinical Trials

print-iconemail-iconshare-icon

For More Information

1-855-RxRxCSS

1-855-797-9277


CSSIFM
El Segundo
2040 East Mariposa Avenue
El Segundo, California 90245
Phone: 213 266 5600
Fax: 562 548 2304

Costa Mesa
1640 Newport Blvd. Suite 370
Costa Mesa, CA 92627
Phone: 949 288 5701
Fax: 949 629 3806

We are not currently accepting walk-ins. Please call to schedule an appointment.